JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Chronic morphine-induced changes in signaling at the A_3 adenosine receptor contribute to morphine-induced hyperalgesia, tolerance and withdrawal.

Timothy M. Doyle[1], Tally M. Largent-Milnes[2], Zhoumou Chen[1], Vasiliki Staikopoulos [3,4,5], Emanuela Esposito[6], Rebecca Dalgarno[7], Churmy Fan[7], Dilip K. Tosh[8], Salvatore Cuzzocrea[6], Kenneth A. Jacobson[8], Tuan Trang,[7] Mark R. Hutchinson[3,4,5], Gary J. Bennett[9], Todd W. Vanderah[2] and Daniela Salvemini[1§]

Department of Pharmacology and Physiology and Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine (T.M.D, Z.C, D.S.), Department of Pharmacology, University of Arizona College of Medicine (T.M.L., T.W.V), Discipline of Physiology, University of Adelaide (V.S. and M.R.H), Institute for Photonics and Advanced Sensing, University of Adelaide (V.S. and M.R.H), ARC Centre of Excellence for Nanoscale BioPhotonics, University of Adelaide (V.S. and M.R.H), Department of Clinical and Experimental Medicine and Pharmacology, University of Messina (E.E. and S.C), Department of Comparative Biology and Experimental Medicine, Department of Physiology and Pharmacology, Hotchkiss Brain Institute, University of Calgary (R.D., C.F. and T.T.), Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (D.K.T. and KJ), Department of Anesthesiology, University of California San Diego (G.B).

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Running Title Page

A_3 adenosine receptor and morphine-induced adverse effects

Corresponding author: E-mail address: daniela.salvemini@health.slu.edu. ORCID ID: 0000-0002-0612-4448. Address: 1402 South Grand Blvd, St. Louis, MO 63104, USA, Phone: 1-314-977-6430, Fax: 1-314-977-6411

Number of pages: 45
Number of tables: 0
Number of figures: 6
Number of references: 70
Word count:
Abstract: 245/250
Introduction: 750/750
Discussion:1058/1500 words

Abbreviations: %MPE - % maximal possible effect; A_1AR – adenosine receptor subtype 1; A_{2A}AR – adenosine receptor subtype 2A; A_{2b}AR – adenosine receptor subtype 2B; A_3AR – adenosine receptor subtype 3; ADK – adenosine kinase; ANOVA – analysis of variance; Cl-IB-MECA - 1-[2-Chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranuronamide; CNS – central nervous system; CSF – cerebrospinal fluid; CCI – chronic constriction injury of the sciatic nerve; DH-SC – dorsal horn of the spinal cord; DTT – dithiothreitol; EDTA - ethylenediaminetetraacetic acid; EGTA - ethylene glycol-bis(β-aminoethyl ether)-tetraacetic acid; ELISA – enzyme-linked immunosorbent assay; HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; IB-MECA - 1-Deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-D-ribofuranuronamide; IFN-γ - interferon-γ; IL-1β - interleukin-1β (IL-1β); IL-10 - interleukin-10; i.p. – intraperitoneal; i.th. – intrathecal; KCl – potassium chloride; LC-MS/MS-MRM - liquid chromatography-mass spectroscopy/mass spectroscopy-multiple reaction monitoring; M3G - morphine-3-glucuronide; M6G - morphine-6-glucuronide; NLRP3 - NOD-like receptor pyrin domain-containing 3; OIH - opioid-induced hyperalgesia P2YR – purinergic G protein-coupled receptor; P2XR – purinergic cation channel; PBS – phosphate buffered saline; PMSF - phenylmethylsulfonyl fluoride; PWL (s) – paw withdrawal latency in seconds; PWT (g) – paw withdrawal threshold in grams force; TNF- tumor necrosis factor.

Section: Neuropharmacology

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Abstract

Treating chronic pain using opioids, such as morphine, is hampered by the development of opioid-induced hyperalgesia (OIH; increased pain sensitivity), antinociceptive tolerance and withdrawal which can contribute to dependence and abuse. In the central nervous system, the purine nucleoside adenosine has been implicated in beneficial and detrimental actions of morphine, but the extent of their interaction remains poorly understood. Here, we demonstrate that morphine-induced OIH and antinociceptive tolerance in rats is associated with a 2-fold increase in adenosine kinase (ADK) expression in the dorsal horn of the spinal cord (DH-SC). Blocking ADK activity in the spinal cord provided greater than 90% attenuation of OIH and antinociceptive tolerance through A_3 adenosine receptor (A_3AR) signaling. Supplementing adenosine signaling with selective A_3AR agonists blocked OIH and antinociceptive tolerance in rodents of both sexes. Engagement of A_3AR in the spinal cord with an ADK inhibitor or A_3AR agonist was associated with reduced DH-SC expression of the NOD-like receptor pyrin domain-containing 3 (NLRP3; 60-75%), cleaved caspase 1 (40-60%), interleukin (IL)-1β (76-80%) and tumor necrosis factor (TNF; 50-60%). In contrast, the neuroinhibitory and anti-inflammatory cytokine IL-10 increased 2-fold. In mice, A_3AR agonists prevented the development of tolerance in a model of neuropathic pain and reduced naloxone-dependent withdrawal behaviors by greater than 50%. These findings suggest A_3AR-dependent adenosine signaling is compromised during sustained morphine to allow the development of morphine-induced adverse effects. These findings raise the intriguing possibility that A_3AR agonists may be useful adjunct to opioids to manage their unwanted effects.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Significance statement.

The development of hyperalgesia and antinociceptive tolerance during prolong opioid use are noteworthy opioid-induced adverse effects that reduce opioid efficacy for treating chronic pain and increase the risk of dependence and abuse. We report that in rodents, these adverse effects are due to reduced adenosine signaling at the A_3AR resulting in NLRP3-IL-1β neuroinflammation in spinal cord. These effects are attenuated by A_3AR agonists; suggesting that A_3AR may be a target for therapeutic intervention with selective A_3AR agonist as opioid adjuncts.

.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Introduction

Acute morphine exposure stimulates μ-opioid receptor-mediated release of the purine nucleoside adenosine from spinal synaptosomes (Cahill et al., 1993). Released adenosine binds four known receptors: G_i-coupled A_1AR and A_3AR and G_s-coupled A_{2A}AR and A_{2B}AR (Fredholm et al., 2001). In the central nervous system (CNS), adenosine signaling exerts potent neuroprotective and anti-inflammatory effects (Borea et al., 2009) and controlled by the balance of extracellular release and intracellular uptake and metabolism (Borea et al., 2009). This balance is governed by the intracellular enzyme adenosine kinase (ADK), where high levels of ADK drive adenosine uptake, reduce extracellular adenosine and compromise adenosine signaling (Boison, 2013) and inhibiting ADK promotes greater extracellular adenosine levels and signaling (Boison, 2013). Hence, ADK acts as the essential “upstream” regulator of adenosine neurotransmission (Boison, 2013).

Our understanding of the interactions between adenosine signaling and opioids, such as morphine, in the CNS is largely limited to A_1AR and A_{2A}AR. Adenosine signaling through A_1AR plays is important for acute morphine antinociceptive effects evidenced by the loss of morphine antinociception following spinal administration of A_1AR antagonists (Sweeney et al., 1987a; Sweeney et al., 1987b; Suh et al., 1997) or in $A_1AR^{-/-}$ mice (Wu et al., 2005). However, reduced A_1AR and A_{2A}AR signaling plays a role in the detrimental effects of opioids. Prolonged use of opioids such as morphine can lead to the development of paradoxical painful hypersensitivity (opioid-induced hyperalgesia, OIH), reduced antinociceptive response to opioids over time (antinociceptive tolerance) (Collett, 1998; Angst and Clark, 2006) and the development

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

of psychological and physical symptoms upon opioid cessation (withdrawal) that undermine the effective use of opioids to treat chronic pain conditions (Collett, 1998; Angst and Clark, 2006). Previous studies reported that prolonged morphine treatment decreases adenosine signaling at A_1AR in the brainstem that corresponded with dependence and addiction behaviors (Zarrindast et al., 1999; Wu et al., 2013). Accordingly, A_1AR agonists or ADK inhibitors attenuate naloxone-precipitated opioid withdrawal behaviors, whereas A_1AR antagonists exacerbate these effects (Zarrindast et al., 1999; Wu et al., 2013). The expression of morphine-induced withdrawal behaviors was attenuated by A_{2A}AR agonists and exacerbated by A_{2A}AR antagonists (Kaplan and Sears, 1996). However, therapeutic use of A_1AR or A_{2A}AR agonists or ADK inhibitors as adjuncts to opioids is not a viable therapeutic approach due to documented A_1AR and A_{2A}AR-mediated cardiovascular side effects (Kiesman et al., 2009; Zylka, 2011).

In contrast, the role of A_3AR in acute or chronic morphine action has not been studied. A_3ARs are expressed by CNS neurons, astrocytes and microglia, including the spinal cord dorsal horn and exert antiinflammatory effects (Janes et al., 2016). Orally bioavailable, small molecule, receptor subtype-selective A_3AR agonists, such as IB-MECA, have been developed (Kim et al., 1994; Jacobson, 1998; Tosh et al., 2012) and advanced to Phase II/III clinical trials for several inflammatory conditions and cancer with a good safety profile (Silverman et al., 2008; Fishman et al., 2012; Stemmer et al., 2013). We have recently reported evidence suggesting that A_3AR agonists reduce the activation of the NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome in the spinal cord linking beneficial effects of A_3AR agonists to the inhibition of NLRP3 inflammasome signaling (Wahlman et al., 2018). NLRP3 inflammasome is a critical

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

complex for the processing of interleukin-1β (IL-1β) (Tsuchiya and Hara, 2014). Over the last several years, compelling evidence supports that underlying the development of opioid-induced hyperalgesia, tolerance, withdrawal, dependence and reward is the imbalance of inflammatory cytokine IL-1β and anti-inflammatory cytokine IL-10 signaling that leads to increased neuronal excitability in the CNS (Hutchinson et al., 2011; Grace et al., 2015; Roeckel et al., 2016). Accordingly, genetic and pharmacological approaches that block IL-1β production and signaling or increase IL-10 signaling have been beneficial in pre-clinical animal studies (Johnston et al., 2004; Shavit et al., 2005; Hutchinson et al., 2011). More recently, Grace and co-workers demonstrated that repeated administration of morphine in rodents can activate NLRP3 inflammasome in the spinal cord (Grace et al., 2016).

Collectively, these data led us to investigate whether adenosine signaling at the A_3AR is compromised during prolonged morphine treatment and contributes to the dysregulation of NLRP3 inflammasome activity in the spinal cord leading to the development of morphine-induced adverse effects. Our findings demonstrate that chronic morphine increases ADK activity and decreases endogenous adenosine at the A_3AR in the spinal cord. Selective A_3AR agonists were found to attenuate morphine-induced adverse effects by downregulating NLRP3 activation in the spinal cord. Our findings identify A_3AR as a target for therapeutic intervention and provide novel mechanistic insights involved in the pathogenesis of morphine-induced hyperalgesia, tolerance and withdrawal.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Materials and Methods

Experimental animals. Male and female Sprague Dawley rats (200-225 g), male CD-1 mice (20-30 g) and male C57BL\6 wild-type mice (20-30 g) were purchased from Harlan Laboratories (Indianapolis, IN, USA) and male $A_3AR^{-/-}$ mice (20-30 g) were obtained from Merck (Whitehouse Station, NJ, USA). Animals were housed in a climate controlled room on a 12 h light/dark cycle with food and water provided *ad libitum*. All experiments were performed in accordance with the guidelines of the International Association for the Study of Pain, and the regulations of the National Institutes of Health (USA) and those of Italy (DM 116192) and the European Union (OJ of EC L 358/112/18/1986). Experimental protocols were approved by the Saint Louis University Institutional Animal Care and Use Committee, the University of Adelaide Animal Ethics Committee (Ethics approval number M-60-2009), the University of Messina Review Board for the Care of Animals and Institutional Animal Care, the University of Arizona Institutional Animal Care and Use Committee, and the University of Calgary Animal Care Committee in accordance with the Canadian Council on Animal Care. All animals were sex, age, and weight-matched, then randomly assigned to treatment groups. To assure reproducibility, animals were split into two to three batches with equal number of animals in each group and behavioral experiments and corresponding biochemical assays were started and performed on different days with experimenters blinded to treatment conditions.

Test compounds. Using a structure-based approach in the design of second generation A_3AR agonists as illustrated in the modeled A_3AR binding complementarity

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

of MRS5698 and MRS5980 (**Supplemental Figure 1**), we have achieved >1000-fold receptor subtype selectivity for A_3AR over other adenosine receptor. The selectivity for A_3AR of these second generation A_3AR agonists greatly exceeds the selectivity of IB-MECA and Cl-IB-MECA, which display 50- to 250-fold selectivity over the other three receptor subtypes in rodents (Tosh et al., 2014; Tosh et al., 2015). MRS5698 (1*S*,2*R*,3*S*,4*R*,5*S*)-4-(6-((3-chlorobenzyl)amino)-2-((3,4-difluorophenyl) ethynyl)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide and MRS5980 (1*S*,2*R*,3*S*,4*R*,5*S*)-4-(2-((5-chlorothiophen-2-yl)ethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1 carboxamide were synthesized as previously described (Tosh et al., 2012). MRS5980 is a more water soluble congener of MRS5698 (Tosh et al., 2012). The remaining compounds are purchased commercially: MRS1523 (3-propyl-6-ethyl-5[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridinecarboxylate; Millipore-Sigma, St. Louis, MO, USA), IB-MECA (1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-D-ribofuranuronamide; Tocris Bioscience, Bristol, UK), morphine sulfate (a kind gift from Mallinckrodt Pharmaceuticals, Saint Louis, MO, USA), ABT-702 dihydrochloride (5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-*d*]pyrimidin-4-amine dihydrochloride, Tocris) and naloxone (Millipore-Sigma).

Delivery of test agents. For morphine administration, rats were lightly anesthetized with 3% isoflurane, maintained on 2% isoflurane in 100% O_2 and an osmotic minipump (Alzet 2001; Alzet Osmotic Pumps, Cupertino CA, USA) primed to deliver 1.0 µl/h saline vehicle (Veh) or morphine at 75 µg/µl/h (~8.2-9 mg/kg/d) over six days was

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

subcutaneously (s.c.) implanted in the interscapular region as described previously (Muscoli et al., 2010). After implantation the animals were singly-housed for the remainder of the experiment.

Intrathecal (i.th.) administration of test agents (10 µl) or their vehicle (3%DMSO; 10 µl) was done through chronic i.th. cannulas implanted as previously described (Muscoli et al., 2010) followed by sterile physiological saline (12 µl) flush. Animals were singly housed following i.th. catheter implantation surgery and allowed to recover for seven days before receiving injections.

Test substances or their vehicle (0.5% methylcellulose/10% DMSO) given by oral gavage were delivered in a 0.2 ml dosing volume.

Defining estrous cycle stage. Given the multi-day nature of the design in freely cycling females, a vaginal smear was taken after the last behavioral time point and stage of estrous defined by cytology as described (Byers et al., 2012). All animals displayed a normal 4-5 day estrous cycle.

Development of morphine-induced thermal hyperalgesia and antinociceptive tolerance in rats.

Thermal hyperalgesia: The development of thermal hyperalgesia was measured in rats by the Hargreaves method (Hargreaves et al., 1988) using a Basile Plantar Test (Ugo Basile Model 37370; Monvalle VA, Italy). The cutoff latencies (20 sec) were set to prevent tissue injury and the heat intensity (IR, 60) was set so as to elicit a 16-18 sec baseline withdrawal latency as previously described (Muscoli et al.,

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

2010). A significant (p<0.05) reduction in paw-withdrawal latency (PWL (s)) over the infusion period time compared to baseline is characterized as thermal hyperalgesia.

Antinociceptive tolerance: Rats received acute intraperitoneal injections of morphine (6 mg/kg) during the period of infusion with morphine or saline on days 1, 3 and 6 (Muscoli et al., 2010). Nociceptive responses were measured using the tail-flick assay (D'Amour and Smith, 1941) 30 minutes after the acute injection of morphine, a time point known to provide a maximal antinociceptive response to acute morphine (Muscoli et al., 2010). The latencies for tail withdrawal from a noxious radiant heat source (Ugo Basile Model 37360; Monvalle VA, Italy) were measured to determine the changes in the antinociceptive effect of the acute morphine challenge as previously described (Muscoli et al., 2010). The cutoff latencies (rats: 10 sec and mice: 15 sec) were set to prevent tissue injury and the heat intensity (IR, 65) was set so as to elicit a 2-4 sec baseline withdrawal latency. Tolerance to the morphine antinociceptive effect was indicated by a significant (P<0.05) reduction in tail-flick latencies 30 min after the acute morphine challenge. Data are reported as the percentage of maximal possible antinociceptive effect (%MPE) with 100% being complete morphine analgesia as calculated by the following equation:

%MPE = (response latency − baseline latency)/(cutoff latency (10 or 15 sec) − baseline latency) × 100.

Naloxone-precipitated withdrawal. Opioid withdrawal behaviors were measured as previously described (Liu et al., 2011). Chronic morphine withdrawal was induced in male Balb/c mice (19-26 g) by repeated intraperitoneal (i.p.) injections of morphine

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

given twice daily (morning and afternoon) for three consecutive days with an escalating dose schedule: D1 (7.5 and 15 mg/kg), D2 (30 and 30 mg/kg), and a single dose on D3 (30 mg/kg). A_3AR agonists or their vehicle (10% DMSO in saline) were co-injected with morphine during the treatment paradigm. A group of control mice received an equal number of saline injections over 3 days; these mice also received the vehicle used for the A_3AR agonists. Naloxone (10 mg/kg, *i.p.*) or its vehicle (saline) was injected 1h after the last morphine or saline injection on D3. The animals were placed into individual Plexiglas observation cylinders (25 cm x 11 cm) and the incidence of jumping, front paw shakes, and hunching indicating withdrawal were recorded for 30 min.

Anti-allodynic Tolerance in the Chronic Constriction Injury Model. Mechano-allodynia was assessed on day 0 prior surgery by probing the plantar aspect of the hind paw with calibrated von Frey filaments (Stoelting, Wood Dale, IL, USA; mice: 0.04–2.00 g; rats: 1.4–26 g) according to the “up-and-down” method (Dixon, 1980) and a paw withdrawal threshold (PWT (g)) was calculated, as previously described (Janes et al., 2014). Chronic constriction injury (CCI) to the sciatic nerve of the left hind leg in mice was then performed under general anaesthesia (Bennett and Xie, 1988). Briefly, CD-1 mice were anesthetized with 3% isoflurane/O_2 and maintained on 2% isoflurane/O_2 during surgery. A small incision (1-1.5 cm in length) was made in the middle of the lateral aspect of the left thigh to expose the sciatic nerve, which was loosely ligated around the entire diameter of the nerve at two distinct sites (spaced 1 mm apart) using silk sutures (6.0).

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

For daily injection studies, after daily baseline behavior measurements were completed animals received an s.c. injection of morphine or saline and co-injections of test compounds or their vehicle and returned to their cage. Mechano-allodynia was then reassessed 1 h after morphine (time of peak antiallodynic effect). Data are reported as the percentage of reversal of mechano-allodynia with 100% being pain behavior on day 0 (d0) prior to CCI and 0% being pain behavior on day 7 (d7) when mechano-allodynia was at a peak using the following equation:

$$\%\text{Reversal of mechano-allodynia} = (PWT(g)_t - PWT(g)_{d7})/(PWT(g)_{d0} - PWT(g)_{d7}) \times 100$$

For minipump studies, after measuring the degree of mechano-allodynia on day 7, minipumps were implanted to deliver morphine or saline with test compound or their vehicle. Mechano-allodynia was reassessed over 14 days corresponding to the life of the minipump. Data are reported as PWT(g).

Analysis of rat plasma samples for morphine content via liquid chromatography-mass spectroscopy/mass spectroscopy-multiple reaction monitoring (LC-MS/MS-MRM). Morphine concentrations were determined at Mallinckrodt Pharmaceuticals from 25 µl plasma using methods previously described (Zou et al., 2009; Kole et al., 2011). LC-MS/MS analysis was performed on a Waters Acquity UPLC system connected to a Sciex API 4000 Q-Trap Mass Spectrometer utilizing the Turbo Ion Spray source in positive ion multiple reaction monitoring mode. Analyst version 1.6 was used to calculate concentrations of analytes which were reported in ng/ml.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Western blot analyses. The dorsal horn of the rat lumbar enlargement of the spinal cord (L4-L6) was harvested, flash frozen in liquid nitrogen, and stored at -80°C. Samples were homogenized in extraction buffer [10 mM HEPES, pH 7.9; 10 mM KCl; 0.1 mM EGTA; 0.1 mM EDTA; 1 mM DTT; 0.5 mM PMSF; 15µg/ml trypsin inhibitor; 3 µg/ml pepstatin A, 2 µg/ml leupeptin, 40 µg/ml benzamidine; 1 mM sodium orthovanadate; Millipore-Sigma] at the highest setting for 2 min; then centrifuged for 15 min at 4°C, as previously described (Paterniti et al., 2012). Protein concentrations were measure by bicinchoninic acid assay (Thermo Fisher Scientific, Carlsbad CA, USA). Proteins were denatured in Laemmli buffer and boiled for 5 min. The proteins (20-40 µg) were resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to nitrocellulose or polyvinylidene fluoride membranes. Membranes were blocked for 2 h at room temperature in 5% non-fat dried milk or 1% bovine serum albumin in 1X PBS, pH 7.4, depending on manufacturer's protocol for antibody and subsequently probed with specific antibodies: anti-ADK (1:500; ThermoFisher Scientific, #PA5-27399), anti-NLRP3 (1:400; Santa Cruz Biotechnology, Santa Cruz CA, USA, #sc-66846) or anti-caspase 1 (1:500; Santa Cruz Biotechnology, #sc-1597) in 1X PBS, 2.5% nonfat dried milk or 0.1% bovine serum albumin and 0.1% Tween-20 at 4ºC overnight. The bound antibodies were then dectected with peroxidase-conjugated bovine anti-mouse IgG secondary antibody (1:3000, Jackson ImmunoResearch, West Grove PA, USA), peroxidase-conjugated goat anti-rabbit IgG (1:3000, Jackson ImmunoResearch,) for 1 h at room temperature. Peroxidase-conjugated antibodies were visualized by enhance chemiluminescence (Bio-Rad, Hercules CA, USA) and

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

documented and quantified for band densitometry using Chemidoc XRS+ documentation system and ImageLab™ software (BioRad). Each membrane was then probed for β-actin (1:5000, Millipore-Sigma) for use as endogenous loading controls.

Cytokine ELISA. The levels of cytokines in spinal cord lysates were assessed using commercially available ELISA kits (R&D Systems, Minneapolis MN, USA) according to manufacturer's protocol.

Statistical analysis. All data collected were analyzed and expressed as mean±SD for *N* animals, as noted. No animal behavior or biochemical data have been excluded. Data collected from each animal was considered a single biological unit and analyzed by two-tailed, Welch's-corrected unpaired t-test, two-way ANOVA with Bonferroni comparisons or one-way ANOVA with Dunnett's comparisons as noted. All data were analyzed using GraphPad Prism (version 5.00 for Windows, GraphPad Software, San Diego CA USA, www.graphpad.com). Significant differences were defined at $P<0.05$.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Results

Antinociceptive effects of acute morphine are not mediated by adenosine signaling at the A_3AR.

Intrathecal administration of MRS1523, a selective A_3AR antagonist (Kreckler et al., 2006), did not prevent the acute antinociceptive actions of morphine used at a dose previously shown to exert near to maximal antinociception when tested in the thermal tail flick assay (D'Amour and Smith, 1941). (**Figure 1A**). Likewise, the acute antinociceptive effects of morphine were similar in A_3AR knockout mice when compared to age and sex-matched wild type mice (**Figure 1B**). Doses of MRS1523 were chosen from our previously published work (Wahlman et al., 2018).

ADK-dependent alterations in A_3AR signaling contribute to OIH and antinociceptive tolerance.

In agreement with our previous study (Muscoli et al., 2010), subcutaneous infusion of morphine over seven days led to a time-dependent reduction in thermal paw withdrawal latencies indicating the development of OIH (**Figure 2A**). Moreover, sustained administration of morphine over the same period decreased the antinociceptive effects to an acute i.p. dose of morphine in a time dependent manner, indicating the development of antinociceptive tolerance (**Figure 2B**). A 2-fold increase in ADK expression in the dorsal horn of the spinal cord was observed at time of peak OIH and tolerance indicative of morphine-induced alterations of adenosine signaling (**Figure 2C**). Attenuating ADK activity with daily i.th. injections of the potent (IC_{50}=1.7 nM) and highly selective non-nucleoside ADK inhibitor, ABT-702 (Lee et al., 2001), prevented the

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

development of OIH and antinociceptive tolerance (**Figures 2A,B**). Daily i.th. co-injections of MRS1523 reduced the beneficial effects of ABT-702 by greater than 50% (**Figures 2A,B**).

To test whether supplementing A_3AR signaling in the spinal cord would attenuate OIH and antinociceptive tolerance, we used the well-characterized A_3AR agonist, IB-MECA (Kim et al., 1994) at a dose that we have previously reported (Ford et al., 2015). Daily i.th. injections of IB-MECA during morphine infusion blocked the development of OIH and antinociceptive tolerance in male rats (**Figure 3A,B**). Oral administration (a preferred clinical route) of IB-MECA (**Figures 3C,D**) or the more selective A_3AR agonist, MRS5698 (Little et al., 2015; Tosh et al., 2015)) (**Figures 3E,F**), during morphine infusion also blocked the development of OIH and antinociceptive tolerance in male rats. The effects of orally administered A_3AR agonists were attenuated by daily intrathecal injection of MRS1523 (**Figures 3C-F**). Moreover, we found similar attenuation of OIH and antinociceptive tolerance in female rats given oral MRS5698 (**Figures 3G,H**). In contrast to their effects on OIH and antinociceptive tolerance, the acute antinociceptive effects of morphine were not potentiated by either IB-MECA or MRS5698 (**Figure 3I**).

A_3AR agonists attenuate morphine-induced NLRP3 activation and IL-1β production and increase IL-10.

We next examined whether the beneficial effects of A_3AR agonists on OIH and antinociceptive tolerance are associated with alterations in morphine-induced NLRP3/IL-1β processing pathways in the spinal cord. At peak OIH and antinociceptive

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

tolerance, the expression of NLRP3 (**Figures 4A,D**) and cleaved caspase 1 (**Figures 4B,E**) in the dorsal spinal cord of rats infused with morphine were increased by greater than 9-fold and 3-fold, respectively. This was accompanied by 3- to 4-fold increase in IL-1β and 3-fold increase in TNF in the spinal cord (**Figures 4C,F**). Inhibiting ADK with i.th. administration of ABT-702 (**Figures 4A-C**) reduced the expression of NLRP3 (3-fold; **Figure 4A**), cleaved caspase 1 (2-fold; **Figure 4B**), IL-1β (5.8-fold; **Figure 4C**) and TNF (2.3-fold; **Figure 4C**) in the dorsal spinal cord of rats infused with morphine. In contrast to the inflammatory cytokines, IL-10 expression was increased with ABT-702 (3-fold; **Figure 4C**). Intrathecal injection of MRS1523 attenuated the beneficial effects of ABT-702 on the expression of NLRP3 (2-fold), cleaved caspase 1 (2-fold), IL-1β (4-fold) and TNF (1.7-fold) (**Figures 4A-C**) and increased IL-10 expression in response to ABT-702 was reduced by 1.6-fold. Oral delivery of MRS5698 had similar effects as ABT-702 did on the expression of NLRP3 (**Figure 4D**), caspase 1 (**Figure 4E**) and cytokines (**Figure 4F**).

A_3AR agonists attenuate morphine-induced anti-allodynic tolerance in neuropathic pain models. Opioids are regarded as second- or third-line treatments for neuropathic pain due in part to the development of opioid adverse effects, yet many patients receive these drugs because first-line treatments are often ineffective (Volkow and McLellan, 2016). We tested whether A_3AR agonists would attenuate morphine-induced adverse effects during treatment in a mouse model of traumatic nerve injury-induced neuropathic pain caused by chronic constriction of the sciatic nerve (CCI) (Chen et al., 2019). Subcutaneous injection of morphine at the time of peak CCI-

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

induced mechano-allodynia (day 7 post-CCI) (Chen et al., 2019) reversed allodynia by approximately 90% (95%CI:84-94%; **Figure 5A**). This anti-allodynic effect gradually disappeared after repeated morphine injections (anti-allodynic tolerance; **Figure 5A**). Co-administration of morphine with a low dose of IB-MECA or MRS5698, which by itself had no antinociceptive effect, blocked the development of anti-allodynic tolerance (**Figure 5A**). In the same animals, tolerance to morphine antinociceptive effects on the normal thermal pain threshold (tail flick assay) was also blocked (**Figure 5B**). These effects were not associated with alterations in plasma levels of morphine metabolites, morphine-3-glucuronide and morphine-6-glucuronide (M3G and M6G; **Figure 5C**), suggesting that morphine pharmacokinetics were unaltered.

To strengthen our findings, we used an additional experimental paradigm coupled with another higher selective A_3AR agonist, MRS5980. On day 7 post CCI in mice, subcutaneous infusion of morphine infusion via a two week osmotic minipump almost completely reversed mechano-allodynia within one day of the start of the infusion; however these anti-allodynic effects were lost in a time-dependent indicating the development of tolerance (**Figure 5D**). Co-infusion of the highly selective A_3AR agonist, MRS5980 maintained the anti-allodynic effects of morphine over 14 days until end of study (**Figure 5D**). No drug effects were observed in the contralateral paw (**Figure 5E**). At the low dose used here, MRS5980 had no effect when given alone (**Figures 5D,E**).

A_3AR agonists attenuate morphine withdrawal behavior. As previously reported (Liu et al., 2011), mice treated for three days with escalating doses of morphine followed by an acute dose of naloxone displayed robust withdrawal behaviors: jumping, front paw

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

shaking and hunched/prayer postures (**Figure 6A**). Daily co-administration of IB-MECA, MRS5698 or MRS5980 with morphine reduced the incidences of these withdrawal behaviors by 2- to 4-fold (**Figure 6B**).

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Discussion

Chronic pain is a significant problem afflicting 1.5 billion people worldwide (Goldberg and McGee, 2011) with an annual financial impact exceeding one trillion dollars. Its treatment is notoriously difficult and often involves prescribing opioids. However, the long-term use of opioids, such as morphine, is limited by emergence of OIH, antinociceptive tolerance and withdrawal that can contribute to dependence and abuse liability (Collett, 1998; Angst and Clark, 2006). Despite these serious side effects, there remains a strong reliance on opioids for pain management (Volkow and McLellan, 2016); making continued investigation of the molecular underpinnings of their adverse effects essential. Our findings are the first to suggest that adenosine signaling through A_3AR is disrupted during prolonged morphine treatment as a consequence of increased ADK expression in the spinal cord. This disruption was evident from our findings that inhibiting ADK attenuated OIH and antinociceptive tolerance with effects partially mitigated by i.th. injections of the A_3AR antagonist, MRS1523. This partial attenuation suggests that other adenosine receptors contribute to beneficial effects of ABT-702, most likely A_1AR, which mediates many protective properties of adenosine (Fredholm et al., 2011; Zylka, 2011; Chen et al., 2013). Accordingly, and perhaps the most noteworthy, our data show that supplementing A_3AR signaling with A_3AR agonists blocked OIH and tolerance in uninjured and nerve-injured rodents. Moreover, our data support previous findings implicating that morphine withdrawal may be dependent on disruption of adenosine signaling (Kaplan and Sears, 1996; Zarrindast et al., 1999; Wu et al., 2013). In addition to the reported beneficial effects of A_1AR and A_{2A}AR activation on preventing the development of opioid dependence behaviors (Kaplan and Sears,

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

1996; Zarrindast et al., 1999; Wu et al., 2013), our data demonstrate that A_3AR is capable of attenuating naloxone-precipitated withdrawal warranting further exploration of this pathway in the context of dependence and reward mechanisms. Since IB-MECA (CF101; piclidenoson) and Cl-IB-MECA (CF102; namodenoson) are already in clinical trials for cancer and inflammatory diseases and have good safety profiles (Muller and Jacobson, 2011), using A_3AR agonists as opioid adjuncts may represent a viable approach to combat the adverse effects in the clinic without the adverse cardiovascular effects exerted by A_1AR and A_{2A}AR agonists (Kiesman et al., 2009; Zylka, 2011).

As we have stated, the development of OIH and antinociceptive tolerance with prolonged morphine treatment are dependent in part on the development of neuroinflammation within the spinal cord (Grace et al., 2015; Roeckel et al., 2016). During neuroinflammation, the reduction of extracellular adenosine due to enhanced intracellular ADK expression/activity (Aronica et al., 2013) coupled with the release of adenosine triphosphate (ATP) (Fiebich et al., 2014) creates an imbalance between antiinflammatory adenosine signaling at A1AR/A_3AR and proinflammatory purinergic signaling at P2YR/P2XR (Rodrigues et al., 2015). For example, ATP activation of P2X7R elicits NLRP3 oligomerization and activation of caspase 1 (Tsuchiya and Hara, 2014), activation of P2X4R modulates microglial activity and activation of P2Y1R increases glutamatergic signaling in neurons and increases reactivity and cell-to-cell calcium flux in astrocytes (Rodrigues et al., 2015). In turn, neuroinflammatory cytokines, such as IL-1β, drive increased ADK expression to maintain this imbalance (Aronica et al., 2011). Morphine-induced IL-1β signaling in the spinal cord leads to the development of OIH, tolerance and withdrawal (Johnston et al., 2004; Shavit et al., 2005; Hutchinson

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

et al., 2011). Exogenous IL-1β has been shown to counter-regulate morphine analgesia while its inhibition prolongs the beneficial effects of morphine (Shavit et al., 2005). The development of OIH and tolerance is associated with increased excitatory glutamate neurotransmission (Lee et al., 2011; Garzon et al., 2012) and IL-1β increases glutamatergic signaling at the synapse by enhancing presynaptic glutamate release (Yan and Weng, 2013) and reducing glial glutamate uptake (Sama et al., 2008). Morphine-induced IL-1β in the spinal cord has also been found to contribute to opioid withdrawal behaviors (Hutchinson et al., 2011). Although we have not explored the mechanisms whereby A_3AR agonists block withdrawal, inhibitory effects on IL-1β are likely based on our current understanding (Liu et al., 2011).

IL-1β can dampen the effects of IL-10 signaling during inflammation. For example, in monocyte/macrophage culture models, IL-1β and another caspase 1-dependent inflammatory cytokine, IL-18, synergize with TNF to enhance interferon-gamma (IFN-γ) production (Raices et al., 2008). IFN-γ, in turn, has been shown to downregulate IL-10 expression (Donnelly et al., 1995) and alter its anti-inflammatory signaling by driving the coupling of IL-10 receptor signaling from STAT3-dependent signaling, which is predominantly anti-inflammatory, to STAT1-dependent signaling, which led to increased expression of TNF and IL-1β (Herrero et al., 2003). Interestingly, activation of A_3AR in mouse RAW264.7 and human THP-1 cells by Cl-IB-MECA has been reported to increase phosphorylation of STAT1 and reduce the inflammatory responses of IFN-γ signaling (Barnholt et al., 2009). To counter-regulate the effects of IL-1β on IL-10, activation of anti-inflammatory IL-10 signaling has been shown to reduce the release of IL-1β by blocking NLRP3 activation (Sun et al., 2019). In a recent study,

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

procyanidins attenuated NLRP3 expression morphine-treated BV-2 microglia and when used in mice, attenuated NLRP3 expression and tolerance (Cai et al., 2016). Our findings suggests that it is likely that the ability of an ADK inhibitor or A_3AR agonist is associated with the relief of suppressive regulation on IL-10 signaling exerted by NLRP3 activation and ensuing IL-1β signaling. Once relieved, IL-10 can provide reported antinociceptive (Johnston et al., 2004; Wu et al., 2018) and antiinflammatory effects (Lin et al., 2010) to mitigate OIH and tolerance. Whether these effects are directly exerted by A_3AR signaling or mediated by other inflammatory pathways, such as IFN-γ, affected by A_3AR signaling is the subject of ongoing studies.

It is well recognized that the antinociceptive effects of morphine are due to adenosine signaling at the A_1AR in the spinal cord (Sweeney et al., 1987a; Sweeney et al., 1987b; Suh et al., 1997; Wu et al., 2005). In contrast to the documented role of the A_1 adenosine receptor subtype in morphine's antinociceptive effects, antinociceptive effects of acute morphine were not due to A_3AR signaling in that responses were not altered in the presence of an A_3AR antagonist or lost in the A_3AR KO mouse. Accordingly, the antinociceptive effects of acute morphine appear to remain dependent on A_1AR. In summary, our work has defined a novel pathway involved in the development of morphine-induced adverse events and has provided a starting point to consider evaluation of A_3AR agonists that are already in clinical trials as adjunct to opioids.

Acknowledgements. We thank Joe McClurg (Mallinckrodt Pharmaceuticals) for plasma M3G/M6G analysis and Veronica Salmaso (NIDDK) for receptor modeling. **Funding.** Studies were supported by NIH funding [Cutting-Edge Basic Research Awards R21 DA040305; DS] and the NIDDK Intramural Research Program (Z01 DK031117-26; KJ).

Competing Financial Interests. DS and GJB are founders of BioIntervene, Inc. which has licensed related intellectual property from Saint Louis University and the National Institute of Health. All other authors declare no competing interests.

Author Contributions.

Participated in research design: Hutchinson, Vanderah, Bennett and Salvemini

Conducted experiments: Doyle, Largent-Milnes, Chen, Esposito, Cuzzocrea, Staikopoulos, Hutchinson, Dalgarno, Churmy Fan, Trang and Vanderah

Contributed new reagents or analytic tools: Tosh and Jacobson

Performed data analysis: Doyle, Largent-Milnes, Hutchinson

Wrote or contributed to the writing of the manuscript: Salvemini, Doyle, Largent-Milnes, Hutchinson, Bennett, Trang, Cuzzocrea, Jacobson and Vanderah.

References

Angst MS and Clark JD (2006) Opioid-induced hyperalgesia: a qualitative systematic review. *Anesthesiology* **104**:570-587.

Aronica E, Sandau US, Iyer A and Boison D (2013) Glial adenosine kinase--a neuropathological marker of the epileptic brain. *Neurochemistry international* **63**:688-695.

Aronica E, Zurolo E, Iyer A, de Groot M, Anink J, Carbonell C, van Vliet EA, Baayen JC, Boison D and Gorter JA (2011) Upregulation of adenosine kinase in astrocytes in experimental and human temporal lobe epilepsy. *Epilepsia* **52**:1645-1655.

Barnholt KE, Kota RS, Aung HH and Rutledge JC (2009) Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. *Journal of immunology (Baltimore, Md : 1950)* **183**:6767-6777.

Bennett GJ and Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. *Pain* **33**:87-107.

Boison D (2013) Adenosine kinase: exploitation for therapeutic gain. *Pharmacological reviews* **65**:906-943.

Borea PA, Gessi S, Bar-Yehuda S and Fishman P (2009) A3 adenosine receptor: pharmacology and role in disease. *Handb Exp Pharmacol*:297-327.

Byers SL, Wiles MV, Dunn SL and Taft RA (2012) Mouse estrous cycle identification tool and images. *PloS one* **7**:e35538.

Cahill CM, White TD and Sawynok J (1993) Morphine activates omega-conotoxin-sensitive Ca2+ channels to release adenosine from spinal cord synaptosomes. *J Neurochem* **60**:894-901.

Cai Y, Kong H, Pan YB, Jiang L, Pan XX, Hu L, Qian YN, Jiang CY and Liu WT (2016) Procyanidins alleviates morphine tolerance by inhibiting activation of NLRP3 inflammasome in microglia. *J Neuroinflammation* **13**:53.

Chen JF, Eltzschig HK and Fredholm BB (2013) Adenosine receptors as drug targets--what are the challenges? *Nature reviews* **12**:265-286.

Chen Z, Doyle TM, Luongo L, Largent-Milnes TM, Giancotti LA, Kolar G, Squillace S, Boccella S, Walker JK, Pendleton A, Spiegel S, Neumann WL, Vanderah TW and Salvemini D (2019) Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain. *Proceedings of the National Academy of Sciences of the United States of America* **116**:10557-10562.

Collett BJ (1998) Opioid tolerance: the clinical perspective. *British journal of anaesthesia* **81**:58-68.

D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. *J Pharmacol Exp Ther* **72**:74-79.

Dixon WJ (1980) Efficient analysis of experimental observations. *Annu Rev Pharmacol Toxicol* **20**:441-462.

Donnelly RP, Freeman SL and Hayes MP (1995) Inhibition of IL-10 expression by IFN-gamma up-regulates transcription of TNF-alpha in human monocytes. *Journal of immunology* **155**:1420-1427.

Fiebich BL, Akter S and Akundi RS (2014) The two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brain. *Front Cell Neurosci* **8**:260.

Fishman P, Bar-Yehuda S, Liang BT and Jacobson KA (2012) Pharmacological and therapeutic effects of A3 adenosine receptor agonists. *Drug discovery today* **17**:359-366.

Ford A, Castonguay A, Cottet M, Little JW, Chen Z, Symons-Liguori AM, Doyle T, Egan TM, Vanderah TW, De Koninck Y, Tosh DK, Jacobson KA and Salvemini D (2015) Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **35**:6057-6067.

Fredholm BB, AP IJ, Jacobson KA, Klotz KN and Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacological reviews* **53**:527-552.

Fredholm BB, AP IJ, Jacobson KA, Linden J and Muller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. *Pharmacological reviews* **63**:1-34.

Garzon J, Rodriguez-Munoz M and Sanchez-Blazquez P (2012) Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance. *Curr Drug Abuse Rev* **5**:199-226.

Goldberg DS and McGee SJ (2011) Pain as a global public health priority. *BMC Public Health* **11**:770.

Grace PM, Maier SF and Watkins LR (2015) Opioid-induced central immune signaling: implications for opioid analgesia. *Headache* **55**:475-489.

Grace PM, Strand KA, Galer EL, Urban DJ, Wang X, Baratta MV, Fabisiak TJ, Anderson ND, Cheng K, Greene LI, Berkelhammer D, Zhang Y, Ellis AL, Yin HH,

Campeau S, Rice KC, Roth BL, Maier SF and Watkins LR (2016) Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. *Proceedings of the National Academy of Sciences of the United States of America* **113**:E3441-3450.

Hargreaves K, Dubner R, Brown F, Flores C and Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain* **32**:77-88.

Herrero C, Hu X, Li WP, Samuels S, Sharif MN, Kotenko S and Ivashkiv LB (2003) Reprogramming of IL-10 activity and signaling by IFN-gamma. *Journal of immunology (Baltimore, Md : 1950)* **171**:5034-5041.

Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF and Watkins LR (2011) Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. *Pharmacological reviews* **63**:772-810.

Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. *Trends in pharmacological sciences* **19**:184-191.

Jacobson KA, Merighi S, Varani K, Borea PA, Baraldi S, Aghazadeh Tabrizi M, Romagnoli R, Baraldi PG, Ciancetta A, Tosh DK, Gao ZG and Gessi S (2018) A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. *Med Res Rev* **38**:1031-1072.

Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, Kamocki K, Doyle T, Snider A, Esposito E, Cuzzocrea S, Bieberich E, Obeid L, Petrache I, Nicol G, Neumann WL and Salvemini D (2014) The development and maintenance of paclitaxel-

induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. *The Journal of biological chemistry* **289**:21082-21097.

Janes K, Symons-Liguori AM, Jacobson KA and Salvemini D (2016) Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics. *British journal of pharmacology* **173**:1253-1267.

Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, Langer S, Martin D, Green P, Fleshner M, Leinwand L, Maier SF and Watkins LR (2004) A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **24**:7353-7365.

Kaplan GB and Sears MT (1996) Adenosine receptor agonists attenuate and adenosine receptor antagonists exacerbate opiate withdrawal signs. *Psychopharmacology* **123**:64-70.

Kiesman WF, Elzein E and Zablocki J (2009) A1 adenosine receptor antagonists, agonists, and allosteric enhancers. *Handb Exp Pharmacol*:25-58.

Kim HO, Ji XD, Siddiqi SM, Olah ME, Stiles GL and Jacobson KA (1994) 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. *Journal of medicinal chemistry* **37**:3614-3621.

Kole PL, Venkatesh G, Kotecha J and Sheshala R (2011) Recent advances in sample preparation techniques for effective bioanalytical methods. *Biomedical chromatography : BMC* **25**:199-217.

Kreckler LM, Wan TC, Ge ZD and Auchampach JA (2006) Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. *J Pharmacol Exp Ther* **317**:172-180.

Lee CH, Jiang M, Cowart M, Gfesser G, Perner R, Kim KH, Gu YG, Williams M, Jarvis MF, Kowaluk EA, Stewart AO and Bhagwat SS (2001) Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor. *Journal of medicinal chemistry* **44**:2133-2138.

Lee M, Silverman SM, Hansen H, Patel VB and Manchikanti L (2011) A comprehensive review of opioid-induced hyperalgesia. *Pain physician* **14**:145-161.

Lin SL, Tsai RY, Tai YH, Cherng CH, Wu CT, Yeh CC and Wong CS (2010) Ultra-low dose naloxone upregulates interleukin-10 expression and suppresses neuroinflammation in morphine-tolerant rat spinal cords. *Behav Brain Res* **207**:30-36.

Little JW, Ford A, Symons-Liguori AM, Chen Z, Janes K, Doyle T, Xie J, Luongo L, Tosh DK, Maione S, Bannister K, Dickenson AH, Vanderah TW, Porreca F, Jacobson KA and Salvemini D (2015) Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. *Brain* **138**:28-35.

Liu L, Coller JK, Watkins LR, Somogyi AA and Hutchinson MR (2011) Naloxone-precipitated morphine withdrawal behavior and brain IL-1beta expression: comparison of different mouse strains. *Brain Behav Immun* **25**:1223-1232.

Muller CE and Jacobson KA (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. *Biochim Biophys Acta* **1808**:1290-1308.

Muscoli C, Doyle T, Dagostino C, Bryant L, Chen Z, Watkins LR, Ryerse J, Bieberich E, Neumman W and Salvemini D (2010) Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **30**:15400-15408.

Paterniti I, Mazzon E, Riccardi L, Galuppo M, Impellizzeri D, Esposito E, Bramanti P, Cappellani A and Cuzzocrea S (2012) Peroxisome proliferator-activated receptor beta/delta agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice. *Surgery* **152**:90-106.

Raices RM, Kannan Y, Sarkar A, Bellamkonda-Athmaram V and Wewers MD (2008) A synergistic role for IL-1beta and TNFalpha in monocyte-derived IFNgamma inducing activity. *Cytokine* **44**:234-241.

Rodrigues RJ, Tomé AR and Cunha RA (2015) ATP as a multi-target danger signal in the brain. *Frontiers in neuroscience* **9**:148-148.

Roeckel LA, Le Coz GM, Gaveriaux-Ruff C and Simonin F (2016) Opioid-induced hyperalgesia: Cellular and molecular mechanisms. *Neuroscience* **338**:160-182.

Sama MA, Mathis DM, Furman JL, Abdul HM, Artiushin IA, Kraner SD and Norris CM (2008) Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. *The Journal of biological chemistry* **283**:21953-21964.

Shavit Y, Wolf G, Goshen I, Livshits D and Yirmiya R (2005) Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. *Pain* **115**:50-59.

Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A,

Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB and Fishman P (2008) Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. *J Rheumatol* **35**:41-48.

Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD and Fishman P (2013) CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. *The oncologist* **18**:25-26.

Suh HW, Song DK and Kim YH (1997) Differential effects of adenosine receptor antagonists injected intrathecally on antinociception induced by morphine and beta-endorphin administered intracerebroventricularly in the mouse. *Neuropeptides* **31**:339-344.

Sun Y, Ma J, Li D, Li P, Zhou X, Li Y, He Z, Qin L, Liang L and Luo X (2019) Interleukin-10 inhibits interleukin-1beta production and inflammasome activation of microglia in epileptic seizures. *J Neuroinflammation* **16**:66.

Sweeney MI, White TD, Jhamandas KH and Sawynok J (1987a) Morphine releases endogenous adenosine from the spinal cord in vivo. *European journal of pharmacology* **141**:169-170.

Sweeney MI, White TD and Sawynok J (1987b) Involvement of adenosine in the spinal antinociceptive effects of morphine and noradrenaline. *J Pharmacol Exp Ther* **243**:657-665.

Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA and Jacobson KA (2012) Structure-guided design of A(3) adenosine receptor-

selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. *Journal of medicinal chemistry* **55**:4847-4860.

Tosh DK, Padia J, Salvemini D and Jacobson KA (2015) Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. *Purinergic signalling* **11**:371-387.

Tosh DK, Paoletta S, Chen Z, Moss SM, Gao ZG, Salvemini D and Jacobson KA (2014) Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor. *Bioorganic & medicinal chemistry letters* **24**:3302-3306.

Tsuchiya K and Hara H (2014) The inflammasome and its regulation. *Critical reviews in immunology* **34**:41-80.

Volkow ND and McLellan AT (2016) Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies. *The New England journal of medicine* **374**:1253-1263.

Wahlman C, Doyle TM, Little JW, Luongo L, Janes K, Chen Z, Esposito E, Tosh DK, Cuzzocrea S, Jacobson KA and Salvemini D (2018) Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms. *Pain* **159**:1025-1034.

Wu H-Y, Mao X-F, Tang X-Q, Ali U, Apryani E, Liu H, Li X-Y and Wang Y-X (2018) Spinal interleukin-10 produces antinociception in neuropathy through microglial β-endorphin expression, separated from antineuroinflammation. *Brain, behavior, and immunity* **73**:504-519.

Wu M, Sahbaie P, Zheng M, Lobato R, Boison D, Clark JD and Peltz G (2013) Opiate-induced changes in brain adenosine levels and narcotic drug responses. *Neuroscience* **228**:235-242.

Wu WP, Hao JX, Halldner L, Lovdahl C, DeLander GE, Wiesenfeld-Hallin Z, Fredholm BB and Xu XJ (2005) Increased nociceptive response in mice lacking the adenosine A1 receptor. *Pain* **113**:395-404.

Yan X and Weng HR (2013) Endogenous interleukin-1beta in neuropathic rats enhances glutamate release from the primary afferents in the spinal dorsal horn through coupling with presynaptic N-methyl-D-aspartic acid receptors. *The Journal of biological chemistry* **288**:30544-30557.

Zarrindast MR, Naghipour B, Roushan-zamir F and Shafaghi B (1999) Effects of adenosine receptor agents on the expression of morphine withdrawal in mice. *European journal of pharmacology* **369**:17-22.

Zou Q, Wei P, Li J, Ge ZX and Ouyang P (2009) Simultaneous determination of 18alpha- and 18beta-glycyrrhetic acid in human plasma by LC-ESI-MS and its application to pharmacokinetics. *Biomedical chromatography : BMC* **23**:54-62.

Zylka MJ (2011) Pain-relieving prospects for adenosine receptors and ectonucleotidases. *Trends in molecular medicine* **17**:188-196.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Legends.

Figure 1. The acute antinociceptive effects are not dependent on A_3AR signaling. (**A**). The antinociceptive effects of an acute dose of morphine (3 mg/kg) in naïve mice were not altered by an i.th. injection of the A_3AR antagonist MRS1523 (1 nmol) given 15 minutes before morphine [$F(1,20)=0.45$, $p=0.51$, $\eta^2_p=0.31$, n=6/group]. (**B**) The antinociceptive effects of acute morphine were similar in $A_3AR^{-/-}$ mice and their control wild-type mice [$F(1,20)=1.3x10^{-29}$, $p=1.0$, $\eta^2_p=1.3x10^{-29}$, n=6/group]. Results are mean±SD and analyzed by two-tailed repeated measures two-way ANOVA with Bonferroni comparisons. **P*<0.05 vs. baseline (BL).

Figure 2. Adenosine signaling at A_3AR in spinal cord is altered during sustained morphine treatment. Morphine infusion, but not saline, caused the time-dependent development of (**A**) thermal hyperalgesia and (**B**) antinociceptive tolerance that was attenuated by daily i.th. administration of ABT-702 (30 nmol/day), but not its vehicle. Daily i.th. injections of the A_3AR antagonist, MRS1523 (1 nmol/day), given 15 minutes before i.th. ABT-702 reduced the effects of ABT-702. (**C**) When compared on day 6 to male rats infused with saline, ADK expression increased in the dorsal horn of the spinal cord harvested from male rats given morphine infusion. Results are mean±SD and analyzed by two-tailed, (**A,B**) repeated measures two-way ANOVA with Bonferroni comparisons or (**C**) unpaired *t*-test with Welch's correction. **A:** $F(9,80) = 14$, $p=3.0 \times 10^{-13}$, $\eta^2_p=0.67$; n=6/group; **B:** $F(9,60) = 39$, $p=2.0 \times 10^{-11}$, $\eta^2_p=0.83$; n=6/group and **C:** $t(7.4) = 15.4$, $p=7.2 \times 10^{-7}$, $d=9.7$; n=5/group. **P*<0.05 vs. day 0, **†***P*<0.05 vs. Veh + Mor and #*P*<0.05 vs. Sal.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 3. A_3AR agonists attenuate morphine-induced hyperalgesia and antinociceptive tolerance. The thermal hyperalgesia (**A**) and antinociceptive tolerance (**B**) that developed in male rats receiving morphine, but not saline, infusion was prevented in rats given daily i.th. administration of IB-MECA (30 nmol/day). (**C-F**) Thermal hyperalgesia (**C,E**) and antinociceptive tolerance (**D**, **F**) was also attenuated by daily oral administration of IB-MECA or MRS5698 (0.3 mg/kg/day). These effects of IB-MECA and MRS5698 (**C,F**) were ablated by daily injection of the A_3AR agonists with MRS1523 (i.th.; 1 nmol/day). (**G,H**) In female rats MRS5698 (0.3 mg/kg/day) also attenuated thermal hyperalgesia (**G**) and antinociceptive tolerance (**H**, *n*=6/group). (**I**) The acute antinociceptive dose response of morphine in naïve male rats to a noxious thermal stimulus (tail-flick) was not altered in rats given an oral dose of IB-MECA or MRS5698 (0.3 mg/kg;) with morphine. Results are mean±SD and analyzed by two-tailed, (**A-D**) repeated measures two-way ANOVA with Bonferroni comparisons, (**E-H**) one-way ANOVA with Dunnett's comparisons, (**I**) the least sum of square method by a 3-parameter, non-linear analysis (Hill-slope =1). **A:** $F(2,8)=109$, $p=1.6 \times 10^{-6}$, $\eta^2_p=0.99$, n=5/group **B:** $F(2,8)=34$, $p=1.2 \times 10^{-4}$, $\eta^2_p=0.97$, n=5/group; **C:** $F(9,36)=19$, $p=2.5 \times 10^{-11}$, $\eta^2_p=0.95$, n=4/group; **D:** $F(9,36)=44$, $p=8.1 \times 10^{-17}$, $\eta^2_p=0.98$, n=4/group; **E:** $F(3,20)=62$, $p=2.6 \times 10^{-10}$, $\eta^2=0.90$, n=6/group; **F:** $F(3,20)=686$, $p=2.5 \times 10^{-20}$, $\eta^2=0.99$, n=6/group; **G:** $F(2,15)=112$, $p=9.7 \times 10^{-10}$, $\eta^2=0.94$, n=6/group and **H:** $F(2,15)=262$, $p=2.1 \times 10^{-12}$, $\eta^2=0.97$, n=6/group. **P*<0.05 vs. day 0 and **†***P*<0.05 vs. Veh + Mor.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 4. ADK inhibitor and A_3AR agonist attenuate morphine-induced NLRP3 inflammasome activation and neuroinflammation. When compared to saline-infused rats, the expression of NLRP3 (**A**), cleaved caspase 1 (**B**), IL-1β (**C**) and TNF (**C**) increased by day 6 in the spinal cords harvested from rats morphine infusion. Daily i.th. ABT-702 (30 nmol/day), but not its vehicle, attenuated these events (**A-C**) and increased IL-10 (**C**). Inhibition of A_3AR signaling with MRS1523 (1 nmol/day) abrogated the effects of ABT-702 (**A-C**). Oral administration of MRS5698 (0.3 mg/kg/day) attenuated morphine-induced NLRP3 (**D**), cleaved caspase 1 (**E**), IL-1β (**F**) and TNF (**F**) and increased IL-10 expression (**F**). The vehicle used for the A_3AR agonist was 10% DMSO in 0.5% methylcellulose. Results are mean±S.D. and analyzed by two-tailed, one-way ANOVA with Dunnett's comparisons**. A:** $F(3,20)=308$, $p=6.8 \times 10^{-17}$, $\eta^2=0.98$, n=6/group; **B:** $F(3,20)=355$, $p=1.7 \times 10^{-17}$, $\eta^2=0.98$, n=6/group; **C:** IL-1β - $F(3,8)=52$, $p=1.3 \times 10^{-5}$, $\eta^2=0.95$, n=3/group; TNF - $F(3,8)=13$, $p=0.0017$, $\eta^2=0.83$, n=3/group; IL-10 - $F(3,8)=34$, $p=6.9 \times 10^{-5}$, $\eta^2=0.95$, n=3/group; **D:** $F(2,15)=179$, $p=3.5 \times 10^{-11}$, $\eta^2=0.96$, n=6/group; **E:** $F(2,15)=158$, $p=8.3 \times 10^{-11}$, $\eta^2=0.95$, n=6/group; **F:** IL-1β - $F(2,12)=66$, $p=3.3 \times 10^{-7}$, $\eta^2=0.92$, n=5/group; TNF - $F(2,12)=29$, $p=2.5 \times 10^{-5}$, $\eta^2=0.83$, n=5/group; IL-10 - $F(2,12)=40$, $p=64.9 \times 10^{-6}$, $\eta^2=0.95$, n=5/group. *$P<0.05$ vs. Veh + Sal, †$P<0.05$ vs. Veh + Mor and §$P<0.05$ vs. ABT-702 + Mor.

Figure 5. A_3AR agonists prevent anti-allodynic tolerance in mice with nerve injury-induced neuropathic pain. (**A-C**)**.** Subcutaneous morphine (3 mg/kg) but not saline injections at the time of peak mechano-allodynia (d7 post-CCI) reversed CCI-induced allodynia in mice, but this reversal gradually disappeared with daily morphine injections

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

(anti-allodynic tolerance) (**A**). Co-injection of IB-MECA or MRS5698 (0.3 mg/kg/day), but not vehicle (10% DMSO in saline), prevented anti-allodynic tolerance (**A**). By themselves, these low doses of A_3AR agonists had no effect on allodynia (**A**). The antinociceptive response to an acute dose of morphine (3 mg/kg, i.p) on day 26 at 30 min post injection in mice that received daily injections of morphine where significantly reduced when compared to mice that received saline injections over the same timeframe indicative of antinociceptive tolerance (**B**). However, antinociceptive tolerance did not develop in mice treated with IB-MECA or MRS5698 combined with morphine (**B**). Plasma morphine metabolite (M3G/M6G) concentrations measured by HPLC 30 minutes after acute morphine (**C**). **D,E** Mechano-allodynia in the paws ipsilateral (**D**) and contralateral (**E**) to CCI in mice that received saline or morphine infusions for one week with MRS5980 (0.3 mg/kg/day) or vehicle (10% DMSO in 0.5% methylcellulose) beginning at peak pain on day 7. Results are mean±SD and analyzed by (**A,D,E**) two-tailed, repeated measures two-way ANOVA with Bonferroni comparisons or two-tailed, one-way ANOVA with Dunnett's comparisons (**B,C**). **A:** $F(3,161)=34$, $p=1.9 \times 10^{-57}$, $\eta^2_p=0.97$, n=3 (Veh + Sal), 4 (Veh + Mor and MRS5698 + Mor) and 6 (IB-MECA + Mor, IB-MECA + Sal and MRS5698 + Sal); **B:** $F(3,20)=76$, $p=4.0 \times 10^{-11}$, $\eta^2=0.92$, n=6/group; **C:** $F(3,20)=0.61$, $p=0.62$, $\eta^2=0.08$, n=6/group; **D:** $F(27,162)=25$, $p=2.1 \times 10^{-44}$, $\eta^2_p=0.96$, n=6 (Veh + Sal, Veh + Mor) and 5 (MRS5980 + Mor, MRS5980 + Mor); **E:** $F(27,162)=1.4$, $p=0.098$, $\eta^2_p=0.59$, n=6 (Veh + Sal, Veh + Mor) and 5 (MRS5980 + Mor, MRS5980 + Mor). **P*<0.05 vs. day 0, **†***P*<0.05 vs. day 7; #*P*<0.05 vs. Veh + Sal or CCI + Sal and §*P*<0.05 vs. CCI + Mor.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 6. A_3AR agonists attenuate morphine withdrawal. (**A**) Incidence of jumping, front paw shakes and hunching withdrawal behaviors in male mice that received escalating morphine over 3 days with daily subcutaneous IB-MECA (0.1 mg/kg; *n*=8) or vehicle (*n*=7/group) [Jumping: $t(10.75) = 2.5$, $p=0.029$, $d=1.3$; Paw shaking: $t(12.86) = 5.1$, $p=2.2\text{x}10^{-4}$, $d=2.6$ and Hunching: $t(12.93) = 6.0$, $p=4.5\text{x}10^{-5}$, $d=3.1$]. (**B**) Incidence of jumping, front paw shakes and hunching withdrawal behaviors in male mice that received escalating morphine over 3 days with daily subcutaneous MRS5698 (0.1 mg/kg; *n*=5), MRS5980 (0.1 mg/kg; *n*=5) or vehicle (*n*=5) [Jumping: $F(2,12)=11$, $p=0.0022$, $\eta^2=0.64$; Paw shaking: $F(2,12)=13$, $p=0.0010$, $\eta^2=0.68$ and Hunching: $F(2,12)=15$, $p=4.9 \text{ x } 10^{-4}$, $\eta^2=0.72$]. The IB-MECA, MRS5698 and MRS5980 doses are below those that have any antinociceptive effect when given alone. Results are mean±SD and analyzed by (**A**) Welch's corrected two-tailed *t*-test or (**B**) two-tailed, one-way ANOVA with Dunnett's comparisons. **P*<0.05 vs. Veh.

JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 1



JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 2



JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 3



JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 4



JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 5



JPET Fast Forward. Published on May 20, 2020 as DOI: 10.1124/jpet.120.000004
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 6





JPET-AR-2020-000004

Supplemental Data

The Journal of Pharmacology and Experimental Therapeutics (JPET)

Chronic morphine-induced changes in signaling at the A_3 adenosine receptor contribute to morphine-induced hyperalgesia, tolerance and withdrawal.

Timothy M. Doyle, Tally M. Largent-Milnes, Zhoumou Chen, Vasiliki Staikopoulos, Emanuela Esposito, Rebecca Dalgarno, Churmy Fan, Dilip K. Tosh, Salvatore Cuzzocrea, Kenneth A. Jacobson, Tuan Trang, Mark R. Hutchinson, Gary J. Bennett, Todd W. Vanderah and Daniela Salvemini



Supplemental Data 1. A visualization of the proposed mode of receptor binding of two highly selective, second generation A_3AR agonists. Predicted interaction of MRS5698 and MRS5980 in the human A_3AR features conserved H-bonding present in agonist-bound A_{2A}AR structures. A hybrid model of the A_3AR, in which the position of transmembrane region 2 (TM2) is taken from the active state of opsin, and the remaining six TM helices are based on the A_{2A}AR (Jacobson et al., 2018). This hybrid model is consistent with the high selectivity of these agonists, because the A_{2A}AR has less structural plasticity than A_3AR in the outer regions (Jacobson et al., 2018). One of three predicted N-glycosylation sites (N12) is shown.

References.

Jacobson KA, Merighi S, Varani K, Borea PA, Baraldi S, Aghazadeh Tabrizi M, Romagnoli R, Baraldi PG, Ciancetta A, Tosh DK, Gao ZG and Gessi S (2018) A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. *Med Res Rev* **38**:1031-1072.